New Delhi: Monoclonal antibody cocktail, used for the treatment of COVID-19, is unlikely to lead to further mutation of the virus, said Dr Raman R Gangakhedkar, former Head Scientist of Epidemiology and Communicable Diseases at the Indian Council of Medical Research (ICMR) on Sunday.Speaking to ANI, Gangakhedkar also said that when a person develops moderate to severe illness, it's more likely due to a dysregulated immune response rather than the virus itself."I don't think that it will lead to mutation theory-wise because we know when the person develops moderate to severe illness we also know that it's more likely due to dysregulated immunity response rather than the virus itself.